876617-06-0

Basic information

• Product Name: (R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate
• Synonyms: (R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate
• CAS NO: 876617-06-0
• Molecular Formula: C₁₁H₂₁NO₂
• Molecular Weight: 199.28994
• EINECS: -0
• Mol File: 876617-06-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate(876617-06-0)
• EPA Substance Registry System: (R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate(876617-06-0)

Safety Data

• Hazardous Substances Data: 876617-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate is used as an intermediate in the synthesis of chiral drugs for its ability to impart specific stereochemistry to the final product, which is crucial for the drug's efficacy and safety.
Used in Organic Synthesis:
(R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate is used as a building block in the production of various organic compounds, leveraging its unique structural features to create complex molecules with specific properties.
Used in Research and Development:
(R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate is utilized in research and development within the pharmaceutical industry, where its chiral nature and versatile reactivity are harnessed to explore new drug candidates and optimize existing ones.
Used in Fine Chemicals Production:
(R)-tert-butyl 2-ethylpyrrolidine-1-carboxylate is employed as a key component in the production of fine chemicals, where its mild odor and clear, colorless liquid state contribute to the quality and purity of the final products.

Upstream product

• 917-54-4 methyllithium 
• 86661-32-7 (S)-tert-butyl 2-((tosyloxy)methyl)pyrrolidine-1-carboxylate 
• 115393-77-6 tert-butyl (S)-2-vinylpyrrolidine-1-carboxylate 
• 132482-09-8 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}-pyrrolidine-1-carboxylate 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 

Downstream Products

• 123168-37-6 (R)-2-Ethylpyrrolidine 
• 460748-80-5 (2R)-2-ethylpyrrolidine hydrochloride 

Relevant articles and documents

2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF

To provide a compound useful as an active ingredient of a pharmacological composition for the treatment of urinary storage symptoms, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors perfected the present invention after discov

2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF

[Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M3 receptor, for example, voiding dysfunctions such as underactive bladder.

2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF

[Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M 3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, for example, voiding dysfunctions such as underactive bladder.

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

FUSED BENZENE DERIVATIVE AND USE

The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.

Direct Asymmetric Synthesis of Quaternary Carbon Centers via Addition-Elimination Process: Nitroolefination of α-Substituted δ-Lactones

The reactions of chiral nitro enamines 2a-c with zinc enolates 4-6 of α-substituted δ-lactones afforded α,α-disubstituted δ-lactones with a high ee through an addition-elimination process.The best results were obtained with the reaction of 2c with 5.Michael-type addition of the enolate onto the nitro enamine is kinetically controlled and decides the absolute stereochemistry of the product.A cyclic transition model is proposed to rationalize the S-selectivity.